newsfilter
← Latest News
GlobeNewswire·

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)A Phase 2 proof-of-concept